Biocon-Viatris deal: Key highlights for investors from the analyst call

There was an incremental downside on Biocon once the analyst call took place at 9 am on Monday morning.

A couple of key concerns that have been brought up with regards to the Biocon-Viatris deal includes the fact regarding valuation; they have paid around 16.7 times EV/EBITDA CY22 estimated and this is versus valuations of 6-7 times for Viatris.

One of the key concerns is debt, the company will be taking on debt of around $1.2 billion on account of this transaction. So the total debt on books will rise to around $1.5 billion because they have $300 million of debt on their books already.